Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image

New

Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Report
180 Pages
May 2025
Region: Global
TechSci Research
ID: 5860456

The Tuberculosis Therapeutics Market was valued at USD 2.18 Billion in 2024, and is expected to reach USD 2.94 Billion by 2030, rising at a CAGR of 5.05%. Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions. With next-generation drug development - particularly in second-line therapies - on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.

Key Market Drivers

High Global Burden of Tuberculosis

The global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability. For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.

Key Market Challenges

Inadequate Funding and Limited Commercial Incentives for Drug Development

The concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low. Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.

Key Market Trends

Shift Toward Shorter, More Effective Treatment Regimens

There is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.

Key Market Players

AstraZeneca PLC
Johnson & Johnson Services, Inc.
Eli Lilly and Company
Mylan Inc.
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd
Pfizer Inc.

Report Scope:

In this report, the Global Tuberculosis Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Therapeutics Market, By Disease Type:

Active TB
Latent TB

Tuberculosis Therapeutics Market, By Therapy:

First-Line Therapy
Second-Line Therapy

Tuberculosis Therapeutics Market, By Route of Administration:

Oral
Parenteral
Others

Tuberculosis Therapeutics Market, By Dosage Form:

Tablets
Capsules
Injection
Others

Tuberculosis Therapeutics Market, By Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Tuberculosis Therapeutics Market, By Region:

North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tuberculosis Therapeutics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Tuberculosis Therapeutics Market Outlook

5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type (Active TB, Latent TB)
5.2.2. By Therapy (First-Line Therapy, Second-Line Therapy)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By Dosage Form (Tablets, Capsules, Injection, Others)
5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map

6. North America Tuberculosis Therapeutics Market Outlook

6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Therapy
6.2.3. By Route of Administration
6.2.4. By Dosage Form
6.2.5. By Distribution Channel
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Tuberculosis Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Therapy
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By Dosage Form
6.3.1.2.5. By Distribution Channel
6.3.2. Canada Tuberculosis Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Therapy
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By Dosage Form
6.3.2.2.5. By Distribution Channel
6.3.3. Mexico Tuberculosis Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Therapy
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By Dosage Form
6.3.3.2.5. By Distribution Channel

7. Europe Tuberculosis Therapeutics Market Outlook

7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Therapy
7.2.3. By Route of Administration
7.2.4. By Dosage Form
7.2.5. By Distribution Channel
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Tuberculosis Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Therapy
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Dosage Form
7.3.1.2.5. By Distribution Channel
7.3.2. United Kingdom Tuberculosis Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Therapy
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Dosage Form
7.3.2.2.5. By Distribution Channel
7.3.3. Italy Tuberculosis Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Therapy
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Dosage Form
7.3.3.2.5. By Distribution Channel
7.3.4. France Tuberculosis Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Disease Type
7.3.4.2.2. By Therapy
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By Dosage Form
7.3.4.2.5. By Distribution Channel
7.3.5. Spain Tuberculosis Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Disease Type
7.3.5.2.2. By Therapy
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By Dosage Form
7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Tuberculosis Therapeutics Market Outlook

8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Therapy
8.2.3. By Route of Administration
8.2.4. By Dosage Form
8.2.5. By Distribution Channel
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Tuberculosis Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Therapy
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Dosage Form
8.3.1.2.5. By Distribution Channel
8.3.2. India Tuberculosis Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Therapy
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Dosage Form
8.3.2.2.5. By Distribution Channel
8.3.3. Japan Tuberculosis Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Therapy
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Dosage Form
8.3.3.2.5. By Distribution Channel
8.3.4. South Korea Tuberculosis Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Disease Type
8.3.4.2.2. By Therapy
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Dosage Form
8.3.4.2.5. By Distribution Channel
8.3.5. Australia Tuberculosis Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Disease Type
8.3.5.2.2. By Therapy
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Dosage Form
8.3.5.2.5. By Distribution Channel

9. South America Tuberculosis Therapeutics Market Outlook

9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Therapy
9.2.3. By Route of Administration
9.2.4. By Dosage Form
9.2.5. By Distribution Channel
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Tuberculosis Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Therapy
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Dosage Form
9.3.1.2.5. By Distribution Channel
9.3.2. Argentina Tuberculosis Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Therapy
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Dosage Form
9.3.2.2.5. By Distribution Channel
9.3.3. Colombia Tuberculosis Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Therapy
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Dosage Form
9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Tuberculosis Therapeutics Market Outlook

10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Disease Type
10.2.2. By Therapy
10.2.3. By Route of Administration
10.2.4. By Dosage Form
10.2.5. By Distribution Channel
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Tuberculosis Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Disease Type
10.3.1.2.2. By Therapy
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Dosage Form
10.3.1.2.5. By Distribution Channel
10.3.2. Saudi Arabia Tuberculosis Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Disease Type
10.3.2.2.2. By Therapy
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Dosage Form
10.3.2.2.5. By Distribution Channel
10.3.3. UAE Tuberculosis Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Disease Type
10.3.3.2.2. By Therapy
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Dosage Form
10.3.3.2.5. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Tuberculosis Therapeutics Market: SWOT Analysis

14. Competitive Landscape

14.1. AstraZeneca PLC
14.1.1. Business Overview
14.1.2. Product & Service Offerings
14.1.3. Recent Developments
14.1.4. Financials (If Listed)
14.1.5. Key Personnel
14.1.6. SWOT Analysis
14.2. Johnson & Johnson Services, Inc.
14.3. Eli Lilly and Company
14.4. Mylan Inc.
14.5. Teva Pharmaceutical Industries Ltd
14.6. Sanofi
14.7. Novartis AG
14.8. Sun Pharmaceutical Industries Ltd
14.9. Pfizer Inc.

15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

AstraZeneca PLC
Johnson & Johnson Services, Inc.
Eli Lilly and Company
Mylan Inc.
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd
Pfizer Inc.

Table Information

Report Attribute	Details
No. of Pages	180
Published	May 2025
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.18 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.94 Billion
Compound Annual Growth Rate	5.0%
Regions Covered	Global
No. of Companies Mentioned	9

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4140EUR$4,500USD£3,466GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€5060EUR$5,500USD£4,237GBP